PerkinElmer announced that it has acquired Geospiza, Inc., a leading developer of software systems for the management of genetic analysis and laboratory workflows delivered through a Web-based secure cloud computing environment.
The acquisition of Geospiza supports PerkinElmer’s growing offerings in Next Generation DNA Sequencing and Analysis Services, which enable researchers to explore the genomic origins of disease more effectively, and help address customers’ growing need to manage knowledge and drive scientific productivity. The addition of Geospiza to PerkinElmer’s sequencing and analysis services will deliver an end-to-end solution that provides scientists access to sequencing services and robust analysis and visualization software, offered through significant capability around cloud computing. This solution enables “anytime, anywhere” genomic data interpretation and analysis, all backed by PerkinElmer expertise and the highest quality standards.
“Genomic information is becoming increasingly important in understanding and treating disease. Making sense of the unprecedented volumes of data generated by next generation sequencing and other biological measurements is critical to improve the disease diagnosis process and drug discovery,” said Richard Begley, PhD, president, Emerging Technologies, PerkinElmer.
He added, “The acquisition of Geospiza, along with existing software in our various diagnostic businesses, gives PerkinElmer a strong platform for offerings in nucleic acid testing. Geospiza is a leader in its industry, and a strong addition to PerkinElmer’s bioinformatics capabilities. We look forward to expanding our family of genetic analysis offerings in research, drug discovery and diagnostics.”
Geospiza’s clients include biotechnology and pharmaceutical companies, universities, researchers, contract core and diagnostic service laboratories involved in genetic testing and manufacturing biotherapeutics.
Source: PerkinElmer, Inc.